NightHawk Biosciences (NYSE:NHWK) Cut to "Hold" at Maxim Group

Maxim Group cut shares of NightHawk Biosciences (NYSE:NHWK – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Monday, The Fly reports.

NightHawk Biosciences Stock Performance

NightHawk Biosciences stock opened at $0.84 on Monday. The firm's 50 day simple moving average is $0.96 and its 200-day simple moving average is $1.22. The company has a market cap of $21.88 million, a P/E ratio of -0.49 and a beta of 0.49. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.60 and a quick ratio of 4.60. NightHawk Biosciences has a fifty-two week low of $0.75 and a fifty-two week high of $3.42.

Institutional Trading of NightHawk Biosciences

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. acquired a new stake in shares of NightHawk Biosciences during the third quarter worth approximately $1,898,000. BlackRock Inc. acquired a new stake in shares of NightHawk Biosciences during the third quarter worth approximately $802,000. State Street Corp acquired a new stake in shares of NightHawk Biosciences during the third quarter worth approximately $178,000. Dimensional Fund Advisors LP acquired a new stake in shares of NightHawk Biosciences during the third quarter worth approximately $160,000. Finally, Millennium Management LLC acquired a new stake in shares of NightHawk Biosciences during the fourth quarter worth approximately $54,000. 9.52% of the stock is currently owned by institutional investors and hedge funds.

About NightHawk Biosciences

(Get Rating)

NightHawk Biosciences, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Further Reading

• Get a free copy of the StockNews.com research report on NightHawk Biosciences (NHWK)
• Hypercharge Networks: Up Triple Digits, But What's The Big Deal?
• 3 Reasons Why Apple's 30% Rally Has Legs
• 3 Reasons to Pick First Citizens Instead of First Republic Bank
• 3 April Earnings Plays for Bullish Swing Traders
• Is Constellation Brands Star About To Rise?

Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.